Antibody-Drug Conjugate Hits Recommended Phase 3 Dose in EGFR-Mutated Lung Cancer
An investigational EGFR x HER3 antibody-drug conjugate showed promising efficacy and a manageable safety profile in previously treated EGFR-mutated lung ...
Tag: EGFR-mutated lung cancer
Osimertinib Alone or With Chemotherapy Tested in Advanced EGFR/TP53-Mutated Lung Cancer
A new randomized phase 3 study suggests that genetic risk profiling could help determine which patients with advanced epidermal growth ...
Cost-Effectiveness of Osimertinib in NSCLC: US Analysis
In recent years, the landscape of cancer treatment has been transformed by the advent of targeted therapies, particularly for non-small ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!